Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, adult, Biological therapies, AML, Non-Biological therapies, elderly, Clinical Research, Chemotherapy, Combination therapy, pediatric, Diseases, neonatal, Therapies, therapy sequence, real-world evidence, registries, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Minimal Residual Disease , Transplantation, molecular testing
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, adult, Biological therapies, AML, Non-Biological therapies, elderly, Clinical Research, Chemotherapy, Combination therapy, pediatric, Diseases, neonatal, Therapies, therapy sequence, real-world evidence, registries, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Minimal Residual Disease , Transplantation, molecular testing
Sunday, December 11, 2022: 4:30 PM-6:00 PM
343-345
(Ernest N. Morial Convention Center)
Moderators:
Jacob M. Rowe, MB, BS, Shaare Zedek Medical Center
and
Terrence Bradley, MD, University of Miami Sylvester Comprehensive Cancer Center
Disclosures:
Rowe: Biosight: Consultancy.
This session includes six abstracts describing both clinical outcomes and new treatment approaches in patients with genetically adverse risk and MRD-positive AML.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH